Skip to main content
Top

Familial Cancer

Issue 4/2005

Content (14 Articles)

BAP1 and Breast Cancer Risk

Isabelle Coupier, Pierre-Yves Cousin, David Hughes, Patricia Legoix-Né, Alexandra Trehin, Olga M. Sinilnikova, Dominique Stoppa-Lyonnet

MLH1 and MSH2 Mutations in Colombian Families with Hereditary Nonpolyposis Colorectal Cancer (Lynch syndrome) – Description of Four Novel Mutations

Alejandro Giraldo, Andrea Gómez, Gustavo Salguero, Herbert García, Fabio Aristizábal, Óscar Gutiérrez, Luis Alberto Ángel, Jorge Padrón, Carlos Martínez, Humberto Martínez, Omar Malaver, Luis Flórez, Rosa Barvo

Mutational analysis of hMsh6 in Israeli HNPCC and HNPCC-like Families

Shiri Dovrat, Arie Figer, Herma H. Fidder, Pavlos Neophytou, Zvi Fireman, Ravit Geva, Jamal Zidan, Dov Flex, Shimon Bar Meir, Eitan Friedman

Long Term Follow-up of HNPCC Gene Mutation Carriers: Compliance with Screening and Satisfaction with Counseling and Screening Procedures

Anja Wagner, Ingrid van Kessel, Mieke G. Kriege, Carli M. J. Tops, Juul Th. Wijnen, Hans F. A. Vasen, Conny A. van der Meer, Iris I. H. van Oostrom, Hanne Meijers-Heijboer

Survival of Patients with Ovarian Cancer due to a Mismatch Repair Defect

Th.E.M. Crijnen, M.L.G. Janssen-Heijnen, H. Gelderblom, J. Morreau, M.A. Nooij, G.G. Kenter, H.F.A. Vasen

Behavioral and Economic Impact of a Familial History of Cancers

Francois Eisinger, Carole Tarpin, Laetitia Huiart, Doug Horsman, Laetitia Rabayrol, Remi Didelot, Claire Julian-Reynier, Hagay Sobol

Short communication

Linkage of a Pedigree Drawing Program and Database to a Program for Determining BRCA Mutation Carrier Probability

Sharon R. Sand, David S. DeRam, Deborah J. MacDonald, Kathleen R. Blazer, Jeffrey N. Weitzel

Short communication

Lack of Germ-line Mutations at the Specific BRCA1-IRIS Coding Sequence in 114 Spanish High-risk Breast/ovarian Families

Miguel de la Hoya, Juan Manuel Fernández, Ana Sánchez de Abajo, Alicia Tosar, Eduardo Díaz-Rubio, Trinidad Caldés

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine